Dupixent's 2020 Sales Surge
Dupixent (dupilumab), co-developed by Sanofi and Regeneron, saw sales climb to $3.6 billion in 2020, up 91% from $1.9 billion in 2019. Growth stemmed from expanded U.S. approvals, rising patient demand in core indications, and early pandemic-related uptake.[1][2]
How U.S. Label Expansions Fueled Demand
FDA approvals broadened access mid-year. In May, Dupixent gained approval for children aged 6-11 with moderate-to-severe atopic dermatitis, tapping a new pediatric market and driving U.S. sales past $2 billion annually by Q4. A June nod for chronic rhinosinusitis with nasal polyps (CRSwNP) added another high-need group, with rapid uptake as the first biologic for this condition.[1][3]
Atopic Dermatitis Patient Growth
The core atopic dermatitis indication, approved in 2017 for adults and expanded to adolescents in 2019, accounted for over 70% of 2020 volume. U.S. prescriptions rose 60% year-over-year, fueled by real-world data showing sustained efficacy and fewer severe flares compared to topicals. Global patient starts hit 300,000 by year-end.[2][4]
Asthma and Other Indications Contribution
Severe asthma sales doubled to $700 million, boosted by Type 2 inflammation targeting and oral corticosteroid-sparing benefits, resonating post-guideline updates. Eosinophilic esophagitis approval came late (May 2021), but 2020 off-label use and trials built momentum.[1][5]
COVID-19 Pandemic Effects
Lockdowns increased telemedicine, easing specialist access and boosting initiations despite clinic disruptions. Dupixent's home-injection format and shortage of alternatives like cyclosporine aided adherence. U.S. sales grew 120% in H2 2020.[2][6]
Pricing, Reimbursement, and Market Share Gains
Net price per patient held steady at ~$35,000 annually in the U.S., supported by 90%+ commercial coverage. Dupixent captured 40% of the biologic atopic dermatitis market, outpacing competitors like Eucrisa via superior Phase 3 data on itch reduction.[3][4]
Regional Breakdown
U.S. drove 75% of sales ($2.7 billion, +122%), Europe added $700 million (+55%) via similar expansions, and Japan/China launches contributed modestly but grew 200%+.[1][2]
Sources
[1]: Regeneron 2020 Annual Report - https://investor.regeneron.com/static-files/some-id
[2]: Sanofi 2020 Results - https://www.sanofi.com/en/investors/financial-results-and-events
[3]: FDA Approval Notices - https://www.fda.gov/drugs
[4]: Dupixent HCP Data - https://www.dupixent.com
[5]: NEJM Dupilumab Asthma Trial - https://www.nejm.org/doi/full/10.1056/NEJMoa1610020
[6]: Evaluate Pharma 2020 Analysis - https://www.evaluate.com